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Background: Atherosclerosis is a complex process involving both genetic and epigenetic factors. The monoamine
oxidase A (MAOA) gene regulates the metabolism of key neurotransmitters and has been associated with
cardiovascular risk factors. This study investigates whether MAOA promoter methylation is associated with
atherosclerosis, and whether this association is confounded by familial factors in a monozygotic (MZ) twin sample.
Methods: We studied 84 monozygotic (MZ) twin pairs drawn from the Vietnam Era Twin Registry. Carotid
intima-media thickness (IMT) was measured by ultrasound. DNA methylation in the MAOA promoter region was
quantified by bisulfite pyrosequencing using genomic DNA isolated from peripheral blood leukocytes. The
association between DNA methylation and IMT was first examined by generalized estimating equation,
followed by matched pair analyses to determine whether the association was confounded by familial factors.
Results: When twins were analyzed as individuals, increased methylation level was associated with decreased IMT
at four of the seven studied CpG sites. However, this association substantially reduced in the matched pair analyses.
Further adjustment for MAOA genotype also considerably attenuated this association.
Conclusions: The association between MAOA promoter methylation and carotid IMT is largely explained by familial
factors shared by the twins. Because twins reared together share early life experience, which may leave a
long-lasting epigenetic mark, aberrant MAOA methylation may represent an early biomarker for unhealthy familial
environment. Clarification of familial factors associated with DNA methylation and early atherosclerosis will provide
important information to uncover clinical correlates of disease.
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Atherosclerosis is a complex process resulting from the
interaction between genetic and non-genetic factors. Des-
pite substantial effort, our understanding of atheroscler-
osis remains incomplete. Epigenetic modifications,
especially DNA methylation, represent an attractive mo-
lecular mechanism for atherosclerosis because they may
be altered in response to environmental exposures and
lifestyle interventions [1]. Indeed, studies in both human
[2,3] and animals [4,5] have reported associations of DNA
methylation variation with subclinical atherosclerosis and* Correspondence: jzhao5@tulane.edu
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reproduction in any medium, provided the oratherosclerotic cardiovascular disease (CVD). However,
specific genes and the epigenetic pathways underlying ath-
erosclerosis remain largely uncharacterized.
Monoamine oxidase A (MAOA), encoded by the X
chromosome, catalyzes the oxidative deamination of bio-
genic amines, such as serotonin, dopamine and norepin-
ephrine, and plays a critical role in maintaining the
metabolic homeostasis of neurotransmitters. Abnormal
MAOA activity has been implicated in several neuro-
psychiatric disorders [6], and recently pancreatic beta
cell function [7] and glucose metabolism [8]. A variable
number of tandem repeats (VNTR) of a 30-bp sequence
located approximately 1.2 kb upstream of the coding re-
gion [9], termed MAOA-uVNTR, has been associated
with psychiatric/behavioral disorders [10,11] andtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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[12], obesity [13], and lipid levels [14]. However, a recent
study failed to detect a relationship between an indivi-
dual’s brain MAOA level and MAOA genotype [15], sug-
gesting that there are additional regulatory mechanisms
that control the expression of MAOA gene.
The purpose of this study is to investigate the associ-
ation between DNA methylation variation in the MAOA
promoter region and carotid atherosclerosis, assessed by
common carotid intima-media thickness (IMT), using a
monozygotic co-twin control design. Because both epi-
genetic variation [16] and carotid atherosclerosis [17]
are under genetic control, it is critical to take into ac-
count any potential shared genetic influences between
DNA methylation and atherosclerosis. In addition, it is
important to control for early family environment be-
cause epigenetic variation is influenced by early life ex-
perience, which may leave long-lasting epigenetic marks
on the epigenome that will likely affect cardiometabolic
risk later in life [18,19]. A monozygotic co-twin control
design controls for shared genes and early family envir-
onment, thus represents a useful model for epigenetic
research of complex traits such as atherosclerosis. As far
as we are aware, this is the first study to examine the as-
sociation between MAOA gene methylation and subclin-
ical cardiovascular disease, and the potential impact of




Twins included in this study were drawn from the
Vietnam Era Twin (VET) Registry, one of the largest
twin registries in the U.S. [20] All twins were male veter-
ans who were born between 1946 and 1956. A total of
307 twin pairs (who were raised in the same household)
were recruited by the Emory Twin Studies (ETS), which
included two companion studies to investigate the role
of psychological, behavioral, and biological risk factors
for subclinical cardiovascular disease in twins. The ETS
include male-male twin pairs, including 187 monozy-
gotic (MZ) pairs and 120 dizygotic (DZ) pairs, with an
inclusion of two samples of twin pairs discordant for
major depression or posttraumatic stress disorder
(PTSD). The ETS protocol has been described elsewhere
[21]. This research was approved by the Emory Institu-
tional Review Board, and all twins signed an informed
consent.
The current analysis included 84 monozygotic twin
pairs from the ETS. These twin pairs were selected
based on the availability of DNA samples and phenotype
data for both members of a twin pair. All twins were
examined in pairs at the Emory University General Clin-
ical Research Center between 2002 and 2010, wheretheir medical history was updated. All twins were
Caucasian. Zygosity information was determined by
DNA analysis.
Risk factor measurements
All measurements were performed in the morning after
an overnight fast, and both members of a pair were
tested at the same time. A medical history and a physical
exam were obtained from all twins. Body mass index
(BMI) was calculated by dividing weight in kilograms by
the square of height in meters. Cigarette smoking was
classified into current smoker (any number of cigarettes)
versus never or past smoker. Pack-years of smoking were
calculated as the number of packs of cigarettes smoked
per day times the number of years smoked. Physical ac-
tivity was assessed by means of a modified version of the
Baecke Questionnaire of Habitual Physical Activity used
in the Atherosclerosis Risk in Communities (ARIC)
Study [22], a 16-question instrument documenting level
of physical activity at work, during sports and non-
sports activities. The total physical activity score was
used in the analysis. Information on alcohol consump-
tion was collected by asking about the number of alco-
holic drinks (beer, wine or liquor) consumed in a typical
week. The total amount of alcohol consumption (in
grams) per week was estimated based on the following
algorithms: 4 oz of wine contains 10.8 g, 12 oz of beer
contains 13.2 g, and 1.5 oz of liquor contains 15.1 g of
ethanol. Hypertension was defined as systolic blood
pressure > 140mmHG or diastolic blood pressure
>90mmHg. Diabetes was defined as fasting blood glu-
cose >126 mg/dL (7.0 mmol/L).
Carotid intima-media thickness (IMT) measurement
Common carotid artery IMT was measured using high
resolution B-mode ultrasonography by standard techni-
ques [23]. Briefly, IMT was quantified both on the near
and far wall at the distal 1.0 cm of the left and right
common carotid arteries proximal to the bifurcation.
For each segment, the sonographer used multiple differ-
ent scanning angles to identify the longitudinal image of
IMT showing the maximum IMT. At least 10 pictures
for each segment were stored digitally, and measure-
ments were made off-line using semi-automated compu-
terized analytical software (Carotid Tools, MIA Inc.,
Iowa City, Iowa) by one observer blinded to other twin
data. Of the stored images, the one with maximum
thickness was selected, and IMT measured, for each seg-
ment. Average values of the IMT of each of the four seg-
ments (right near and far walls, and left near and far
walls) were used as the IMT values for each twin in the
analysis (total mean of maximum IMT). In order to
minimize error, the same technician did IMT measure-
ments throughout the study, and the same equipment
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the twin participants. In our lab, the mean absolute dif-
ference in IMT measured in 7 subjects in whom 2 ca-
rotid artery examinations were performed 3 days apart,
was 0.03 (±0.02) mm. The mean difference in 2 succes-
sive readings of the same 10 segments of common carotid
IMT was 0.02 (±0.02) mm with a Pearson correlation
coefficient of 0.93.
DNA methylation analyses by quantitative bisulfite
pyrosequencing
Genomic DNA was isolated from peripheral blood leuko-
cytes by standard method. DNA methylation level in the
MAOA gene promoter region was determined using
quantitative bisulfite pyrosequencing by the EpigenDx Inc
(Worcester, MA), a company specializing in epigenetic
analysis by pyrosequencing. Briefly, the human MAOA
promoter methylation assay covered seven CpG dinucleo-
tides in the promoter region ranging from −749 base pair
(bp) to −675 bp from the transcriptional start site (TSS),
based on Ensembl Gene ID ENSG00000189221 and the
Transcript ID ENST00000338702. To sequence these
selected CpG sites, we designed one pyrosequencing assay
and tested for PCR preferential amplification and quanti-
tative pyrosequencing analysis. Figure 1 schematically
illustrates the target CpG sites by pyrosequencing assay
with respect to transcription start site (TSS) and the
MAOA-uVNTR polymorphism.
The bisulfite conversion was performed with 500 ng
genomic DNA using the EZ DNA methylation kit
(ZymoResearch, Inc., CA). The PCR reaction was per-
formed with 0.2 μM of each primer with one of the PCR
primers being biotinylated to purify the final PCR prod-
uct using Sepharose beads. The PCR product was bound
to Streptavidin Sepharose HP (Amersham Biosciences,
Uppsala, Sweden), and the Sepharose beads containing
the immobilized PCR product were purified, washed and





Figure 1 A schematic illustration for the CpG sites in a promoter regi
MAOA-uVNTR variant. The sequence shown represents a 75 bp fragment
1–7 refer to locations of the CpG sites assayed in this study. TSS: Transcriptusing the Pyrosequencing Vacuum Prep Tool (Pyrose-
quencing, Qiagen) as recommended by the manufacturer.
Then 0.5 μM Pyrosequencing primer was annealed to the
purified single-stranded PCR product. 10 μl of the PCR
products were sequenced by Pyrosequencing PSQ96 HS
System (Pyrosequencing, Qiagen) following the manufac-
turer’s instructions (Pyrosequencing, Qiagen). The methy-
lation status of each CpG site was analyzed individually as
an artificial T/C SNP using QCpG software (Pyrosequen-
cing, Qiagen). Methylation level at each CpG site was cal-
culated as the percentage of the methylated alleles over
the sum of methylated and unmethylated alleles. The
mean methylation level was calculated using methylation
levels of all measured CpG sites within the targeted re-
gion of the gene. Pyrosequencing assay was done on
duplicate samples, with a correlation of over 99.8% be-
tween the two runs for a same sample. For quality con-
trol, each experiment included non-CpG cytosines as
internal controls to verify efficient sodium bisulfite
DNA conversion. We also included unmethylated and
methylated DNAs as controls in each run. In addition,
we performed PCR bias testing using Pyrosequencing
by mixing the unmethylated DNA control and in vitro
methylated DNA at different ratios (0, 20%, 40%, up to
100%) followed by bisulfite modification, PCR and pyro-
sequencing analysis. The percent methylation obtained
from the mixing study showed high correlation with
expected methylation percentages with a correlation coeffi-
cient of 0.97, indicating high quality methylation data.Genotyping of the MAOA-uVNTR variant
To examine whether the association between MAOA
methylation variation and IMT is modified by the
MAOA-uVNTR, we genotyped the MAOA-uVNTR vari-
ant according to the method described previously [24]. In
brief, genomic DNA was amplified with forward primer




on of MAOA gene assayed in this study in relation to the
(−749 to −675 with respect to TSS) in the 50-UTR of MAOA. Numbers
ional Start Site; ATG: Translational Start Codon.
Table 1 Demographic, clinical and laboratory
characteristics of the twins
Variable Mean ± SD or %
Age (years) 55.1 ± 2.8
Type 2 diabetes (%) 11.4
Hypertension (%) 36.5
Current smoking (%) 37.6
Body mass index (kg/m [2])) 29.4 ± 4.8
Systolic blood pressure (mmHg) 129.3 ± 17.5
Diastolic blood pressure (mmHg) 81.4 ± 11.6
High density lipoprotein cholesterol (mg/dL) 37.6 ± 10.7
Low density lipoprotein cholesterol (mg/dL) 123.3 ± 36.8
Total triglyceride (mg/dL) 177.5 ± 102.5
Total mean of maximum intima-media
thickness (μm)
769.7 ± 121.8
Mean MAOA methylation level (%) 5.0 ± 1.6
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GACGCTCCATTCGGA -30, with PCR thermal cycling
conditions of 10-min denaturation at 95°C, then 35 cycles
of 95°C for 30 sec, 60°C for 30 sec and 72°C for 1 min.
This was followed by 5-min extension at 72°C. Amplified
PCR products were visualized on a capillary-based
ABI3100 Genetic Analyzer along with GeneScan 500
ROX as sizing standard. Data collection and allele scoring
was performed using GeneScan 3.7 and Genotyper 3.7
(Applied Biosystems). PCR products included 2 repeated
sequences in 3 and 4 repeats.
Statistical analyses
Prior to analysis, continuous variables including IMT
and methylation data were logarithmically transformed
to improve normality. To adjust for multiple testing,
we used the Benjamini-Hochberg false discovery rate
(FDR) procedure [25] to correct for the number of
CpG sites evaluated and used an FDR-adjusted P
value (q value) threshold of 0.05 to determine statis-
tical significance. The PROC MULTTEST procedure
in SAS 9.2 was used to calculate the adjusted-FDR
(the q-value method).
1) Regression analysis by treating twins as individuals:
We examined the association of methylation level at
each CpG site and the mean methylation level of all
measured CpG sites with carotid IMT, adjusting for
age, smoking, BMI, diabetes, HDL, LDL, systolic
blood pressure, and physical activity level. These
analyses were done using generalized estimating
equation (GEE) models, in which carotid IMT was
the dependent variable, DNA methylation level was
the independent variable, and twin pair was included
as a clustering variable to account for the within
twin pair correlations.
2) Matched pair analyses by considering twins as
members of a twin pair: To examine whether the
association between DNA methylation and IMT was
explained by shared genetic and/or familial
environment, we conducted matched pair analysis
by treating twins as members of a twin pair. First,
we calculated the intrapair difference in DNA
methylation level, defined as the difference in DNA
methylation between two members of a twin pair.
The intrapair differences in IMT and other
continuous variables were similarly calculated.
Then we conducted linear regression by regressing
the intrapair difference in IMT (dependent variable)
on the intrapair difference in methylation level
(independent variable) at each CpG site, adjusting
for intrapair differences in smoking (pack-year), BMI,
HDL, LDL, systolic blood pressure and level of
physical activity.3) Sensitivity analyses: As described before, our sample
included twins recruited by two projects with
oversampling of twins with major depression or
PTSD. To examine whether the oversampling
scheme influences our results, we performed
separate analyses by further adjusting for depressive
symptoms (as measured by Beck Depressive
Inventory scores) or PTSD (n = 35 including 9 pairs
and 17 singletons). To evaluate the potential impact
of MAOA-uVNTR genotype on the association
between methylation variation and IMT, we
conducted separate analyses by further controlling
for this genotype in statistical models. To determine
whether combining data from the two studies has an
impact on our results, we included study affiliation
(THS or SAVEIT) as a covariate in the statistical
analyses. In addition, we conducted sensitivity
analysis to examine whether batch effects influence
our results by including an indicator variable for
sample batches (plate 1 vs. plate 2) in the statistical
analysis.
Results
The age of the twins ranged from 48 to 61 years with a
mean of 55. Twins included in the current analysis were
not different from those not included in terms of IMT
and other covariates. Table 1 presents the demographic
characteristics of the twins included in this analysis.
The mean methylation level of the seven CpG sites
examined in MAOA promoter was 5.0%, with the high-
est and lowest methylation levels occurring at CpG site
5 (7.2%) and site 1 (3.7%), respectively. Methylation
levels of the seven CpG sites in MAOA promoter were
highly correlated with each other (correlation ranges
from 0.77 to 0.93, all p’s <0.0001). Carotid IMT was
Table 3 Association between carotid IMT and MAOA
methylation variation by multivariate GEE
Position β P* P‡
1 −0.07 0.04 0.07
2 −0.08 0.02 0.03
3 −0.06 0.14 0.20
4 −0.06 0.05 0.08
5 −0.10 0.03 0.05
6 −0.06 0.15 0.23
7 −0.06 0.10 0.14
Mean −0.09 0.02 0.06
β:regression coefficient; * P values adjusted for multiple testing and covariates,
including age, smoking, BMI, diabetes, LDL, HDL, SBP and physical activity;
‡Further adjusting for MAOA genotype.
Zhao et al. BMC Medical Genetics 2012, 13:100 Page 5 of 8
http://www.biomedcentral.com/1471-2350/13/100negatively correlated with methylation variation at five
of the seven studied CpG sites (Table 2). Mean MAOA
promoter methylation was also inversely correlated with
carotid IMT (correlation = − 0.17, p = 0.03).
1) Results of multivariate GEE by treating twins as
individuals: DNA methylation levels at four CpG
sites in the MAOA promoter showed significant
individual association with IMT after adjusting for
known coronary risk factors (all p’s ≤ 0.05). The
mean MAOA methylation level was also significantly
associated with carotid IMT (p = 0.02). On average, a
10% increase in the mean MAOA methylation level
was associated with a decrease of 115 μm (95% CI:
36, 195) in carotid IMT. In the multivariate GEE
models, age (p = 0.01) and systolic blood pressure
(p = 0.002) were also significantly and positively
associated with carotid IMT. Further adjustment for
the MAOA-uVNTR genotype attenuated the
association between MAOA methylation and IMT.
Results for multivariate GEE analyses are shown in
Table 3.
2) Results by matched pair analyses: DNA methylation
levels of the two members within a twin pair were
highly correlated at each of the examined CpG site
(all p’s < 0.0001). The mean methylation level of the
twins within a pair was also significantly correlated
(r = 0.38, p = 0.0004). Regression analysis using
intrapair differences demonstrated that methylation
variation at none of the seven CpG sites was
associated with IMT, suggesting that the association
observed in individual analysis is largely explained by
genetic similarity or other familial factors shared by
the twins. Results for matched pair analyses are
shown in Table 4.
3) Results for sensitivity analyses: Additional
adjustment for depression or PTSD in matched pair








(Relative to TSS, bp) (%, mean ± SD) (P value)
1 43514718 (−749) 3.70 ± 1.83 −0.17 (0.03)
2 43514729 (−738) 3.73 ± 1.60 −0.22 (0.005)
3 43514740 (−727) 5.44 ± 1.72 −0.10 (0.12)
4 43514748 (−719) 4.34 ± 1.76 −0.20 (0.01)
5 43514773 (−694) 7.24 ± 1.84 −0.16 (0.04)
6 43514782 (−684) 5.61 ± 1.79 −0.15 (0.05)
7 43514791 (−674) 4.67 ± 1.92 −0.12 (0.13)
Mean 4.96 ± 1.65 −0.17 (0.03)
*On chromosome X according to GCRh37/hg19.adjustments of the study affiliation (THS or SAVEIT)
or the MAOA-uVNTR genotype did not change
our results.
Discussion
We found that DNA methylation variation in the
MAOA promoter region is associated with carotid ath-
erosclerosis when twins were treated as individuals, but
the association substantially attenuated when twins were
analyzed in pairs, a statistical method that effectively
controls for genetic background (which is identical in
MZ twins) and other familial factors. These results sug-
gest that genetic predisposition and/or shared family en-
vironment could confound the relationship between
MAOA promoter methylation and carotid atheroscler-
osis, or represent important antecedents to this
association.
There are several ways through which familial factors
may affect the relationship between DNA methylation
and early atherosclerosis. First, there could be familial
confounding factors. For example, children raised in
families with low socio-economic status (SES) may have
an increased risk of subsequent CVD [26,27], whereas










β:regression coefficient; *Adjusted for intrapair differences in smoking
(pack-years), BMI, LDL, HDL, blood pressure and physical activity.
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ther adjustments for levels of education and socioeco-
nomic status in adulthood did not affect the relationship
between MAOA methylation and IMT. While childhood
socioeconomic indicators were not available in our sam-
ple, these familial factors were accounted for in the
matched pair analyses because twins were raised in the
same family during childhood. Because the association
between MAOA methylation and IMT substantially
reduced after accounting for familial factors, our find-
ings indicate that factors shared by the twins (genetic,
parental, maternal, and/or other familial environment)
may be important in the link between MAOA methyla-
tion variation and atherosclerosis. Second, familial fac-
tors may be necessary antecedents to epigenetic
alterations or subclinical atherosclerosis [29,30]. Because
monozygotic twins are matched on genetic and/or early
life family environment, our pairwise analysis effectively
controls for these factors.
Recent studies in monozygotic twins have reported
associations between DNA methylation variation and
human diseases, such as type 1 diabetes [31], psychotic
disorders [32,33] and systemic lupus erythematosus [34],
indicating that epigenetic variability may contribute to
phenotypic discordance between genetically identical
individuals [35,36]. Our group also reported associations
between global DNA methylation and insulin resistance
[37], and between serotonin transporter gene (SLC6A4)
promoter methylation and obesity measures [38] in this
same monozygotic twin sample. The familial confound-
ing identified in this study, however, does not contradict
previous findings. First, monozygotic twins may not be
exactly identical [39] and stochastic origins of DNA
methylation variation are possible in MZ twins. The two
members of a monozygotic pair may harbor subtle gen-
etic differences, such as copy number variation [39], that
are associated with an increased level of epigenetic sto-
chasticity. Indeed, a recent large-scale DNA methylation
profiling in twins indicates that stochastic epigenetic
variation may be more common than we previously
appreciated [40]. Second, environment exposed to the
two identical twins may not be exactly the same, and en-
vironment unique to each member, e.g., disparity in pla-
centa blood supply, may induce epigenetic variation that
could potentially increase disease risk. Third, the familial
confounding found in this study may represent a
disease- and/or gene-specific phenomenon, but not
representing the case of other diseases or genes.
In this study, we observed that DNA methylation at
particular CpG sites showed considerable variability
within monozygotic twin pairs (intrapair difference
ranges from −0.08 to −0.24). This agrees with findings
by other investigators [31,32]. In addition, the magnitude
of DNA methylation variation is relatively small comparedto DNA methylation alterations generally observed in can-
cer. However, the magnitude of methylation variation in
our study is comparable to many of the previous studies
on nonmalignant complex disorders [31,34,38,40-44]. It is
possible that epigenetic variation at multiple CpG sites
may be involved in the pathogenesis of complex disease,
but each individually confers only a small risk effect to dis-
ease. This observation most likely reflects the norm for
most human complex disorders and parallels with findings
from genome-wide association studies in which many gen-
etic variants contribute to disease risk but the predicted
risk associated with each variant is generally small.
A previous study has shown that smoking is closely
related to MAOA activity and may also influence MAOA
promoter methylation [45]. In this study, however, we
did not find a relationship between smoking status and
methylation level at any of the examined CpG sites. This
may reflect a site-specific epigenetic effect on smoking
because the two studies examined different CpG sites in
the MAOA promoter region (~39kb apart). The lack of
association between MAOA methylation and smoking
may also be due to low statistical power of our analysis.
However, to our best knowledge, the use of 84 monozy-
gotic twin pairs in our study represents one of the largest
epigenetic twin studies performed for any complex dis-
ease phenotype to date.
Our study has a number of limitations that should be
considered when interpreting the data presented here.
First, because of practical difficulties in obtaining coron-
ary artery tissues from living individuals, methylation
levels were tested in peripheral blood leukocytes, but
not directly from arteries or atherosclerotic tissues.
Therefore, our results may not provide a direct index of
methylation in the vascular system. In addition, our epi-
genetic data were collected from DNA derived from
whole blood leukocytes, which includes a heterogeneous
mixture of cell types; as such, we were unable to assess
methylation status specific to blood cells. Second, our
sample included twins with oversampling of either major
depression or PTSD, both of which may influence CVD
risk. However, the observed associations between aber-
rant DNA methylation and subclinical CVD are unlikely
to be confounded by depression or PTSD because fur-
ther adjustment for these two psychiatric conditions did
not change the results. Third, DNA methylation influ-
ences disease risk through regulating gene expression,
which could not be evaluated in our study due to lack of
fresh leukocytes or atherosclerotic tissues. Additionally,
we could not assess the relationship between DNA
methylation and platelets MAOA activity due to lack of
platelets samples for the twins. The association of DNA
methylation with MAOA gene expression should be
investigated in future study. Fourth, we only focused on
a small region in the promoter of MAOA gene, whereas
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influence disease susceptibility. These regions should be
examined in future research. Fifth, our sample size is
relatively small which may potentially limit our power in
detecting the shared familial factors. However, to the
best of our knowledge, a sample size of 84 monozygotic
twin pairs represents the largest possible sample size for
a matched co-twin control analysis. Finally, our twin
sample was derived from a middle-aged sample of male
military veterans; therefore, the generalizability to
females and other younger or older populations is
unknown.
Conclusions
In summary, in a matched monozygotic twin sample, we
found that the association between MAOA promoter
methylation and carotid atherosclerosis is largely
explained by genetic predisposition and/or family envir-
onment shared by the twins. Familial factors, e.g., gen-
etic, parental nutrition, maternal care, and other familial
environment, may be a key element that could poten-
tially increase future risk of atherosclerosis through the
epigenome. Disentangling epigenetic effects from the
confounding influences of genetic and/or familial envir-
onmental heterogeneity is critical in elucidating the etio-
logical role of epigenetic variation in disease
development and may also provide important informa-
tion to uncover clinical correlates of disease.
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